Revance Therapeutics | SCHEDULE 13D/A: Others
Revance Therapeutics | SC 14D9: Tender offer solicitation/recommendation statements filed under Rule 14d-9
Revance Therapeutics | SC TO-T: Third party tender offer statement
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | SC TO-C: Written communication relating to an issuer or third party tender offer
Revance Therapeutics | SC14D9C: Written communication by the subject company relating to a third party tender offer
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hollander David
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 10-Q: Q3 2024 Earnings Report
Revance Therapeutics | 8-K: Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | SCHEDULE 13G/A: Others
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GIC Private Limited(0%)
Unlock the Full List